Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer
Objective: The aim of this study is to reveal the relationship and correlation between the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) risk models used to determine first-line treatment in metastatic mRCC and, les...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2025-08-01
|
| Series: | Forbes Tıp Dergisi |
| Subjects: | |
| Online Access: | https://forbestip.org/articles/comparison-of-prognostic-risk-models-imdc-mskcc-cff-in-patients-diagnosed-with-metastatic-renal-cell-cancer/doi/forbes.galenos.2025.78309 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849391773694033920 |
|---|---|
| author | Merve KESKİNKILIÇ Kübra CANASLAN Hüseyin Salih SEMİZ Tuğba YAVUZŞEN |
| author_facet | Merve KESKİNKILIÇ Kübra CANASLAN Hüseyin Salih SEMİZ Tuğba YAVUZŞEN |
| author_sort | Merve KESKİNKILIÇ |
| collection | DOAJ |
| description | Objective: The aim of this study is to reveal the relationship and correlation between the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) risk models used to determine first-line treatment in metastatic mRCC and, less commonly, the Cleveland Clinic Foundation (CCF) prognostic risk model.
Methods: The IMDC, MSKCC and CCF scores of mRCC patients who received immunotherapy (IO) and molecular targeted therapy were calculated retrospectively at the time of diagnosis.According to the score results, the patients were grouped as favorable,intermediate and poor risk.According to these risk groups,the median progression-free survival (mPFS) and median overall survival (mOS) of the patients were calculated and the correlation with each other was considered significant using appropriate statistical analyses, and p<0.05 was considered significant.
Results: The median follow-up time of 189 patients in the study was 45.5 months, mPFS 23.6 months [95% confidence interval (CI): 18.6-28.5 months] and mOS 34.6 months (95% CI: 23.3-45.9 months).The distribution of patients according to risk groups was similar in all three prognostic risk models. In the poor-risk group, both mPFS and mOS were statistically significantly shorter according to all three risk models (mPFS, IMDC: 14.2 months, MSKCC: 15.6 months, CCF: 17.1 months; mOS, IMDC: 17.6 months, MSKCC: 17.7 months, CCF: 22.4 months, p<0.001). A statistically significant positive correlation was observed between CCF, MSKCC and IMDC (r=0.656 vs. r=0.690, p<0.001). A stronger and statistically significant positive correlation was observed between MSKCC and IMDC (r=793, p<0.001).
Conclusion: Our study is the first study in the literature that we know of comparing the IMDC, MSKCC and CCF risk models in mRCC receiving IO and targeted therapy and as a result of our study, it was shown that all three risk models were correlated with each other. |
| format | Article |
| id | doaj-art-56716632a5cc4d9faf1d56db1332c296 |
| institution | Kabale University |
| issn | 2757-5241 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Forbes Tıp Dergisi |
| spelling | doaj-art-56716632a5cc4d9faf1d56db1332c2962025-08-20T03:40:57ZengGalenos YayineviForbes Tıp Dergisi2757-52412025-08-016218018710.4274/forbes.galenos.2025.78309Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell CancerMerve KESKİNKILIÇ0https://orcid.org/0000-0002-3342-3144Kübra CANASLAN1https://orcid.org/0000-0001-7705-3926Hüseyin Salih SEMİZ2https://orcid.org/0000-0002-7083-8517Tuğba YAVUZŞEN3https://orcid.org/0000-0001-9375-8133Dokuz Eylül University Faculty of Medicine Department of Internal Medicine, Division of Medical Oncology, İzmir, TürkiyeDokuz Eylül University Faculty of Medicine Department of Internal Medicine, Division of Medical Oncology, İzmir, TürkiyeDokuz Eylül University Faculty of Medicine Department of Internal Medicine, Division of Medical Oncology, İzmir, TürkiyeDokuz Eylül University Faculty of Medicine Department of Internal Medicine, Division of Medical Oncology, İzmir, TürkiyeObjective: The aim of this study is to reveal the relationship and correlation between the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) risk models used to determine first-line treatment in metastatic mRCC and, less commonly, the Cleveland Clinic Foundation (CCF) prognostic risk model. Methods: The IMDC, MSKCC and CCF scores of mRCC patients who received immunotherapy (IO) and molecular targeted therapy were calculated retrospectively at the time of diagnosis.According to the score results, the patients were grouped as favorable,intermediate and poor risk.According to these risk groups,the median progression-free survival (mPFS) and median overall survival (mOS) of the patients were calculated and the correlation with each other was considered significant using appropriate statistical analyses, and p<0.05 was considered significant. Results: The median follow-up time of 189 patients in the study was 45.5 months, mPFS 23.6 months [95% confidence interval (CI): 18.6-28.5 months] and mOS 34.6 months (95% CI: 23.3-45.9 months).The distribution of patients according to risk groups was similar in all three prognostic risk models. In the poor-risk group, both mPFS and mOS were statistically significantly shorter according to all three risk models (mPFS, IMDC: 14.2 months, MSKCC: 15.6 months, CCF: 17.1 months; mOS, IMDC: 17.6 months, MSKCC: 17.7 months, CCF: 22.4 months, p<0.001). A statistically significant positive correlation was observed between CCF, MSKCC and IMDC (r=0.656 vs. r=0.690, p<0.001). A stronger and statistically significant positive correlation was observed between MSKCC and IMDC (r=793, p<0.001). Conclusion: Our study is the first study in the literature that we know of comparing the IMDC, MSKCC and CCF risk models in mRCC receiving IO and targeted therapy and as a result of our study, it was shown that all three risk models were correlated with each other.https://forbestip.org/articles/comparison-of-prognostic-risk-models-imdc-mskcc-cff-in-patients-diagnosed-with-metastatic-renal-cell-cancer/doi/forbes.galenos.2025.78309cleveland clinic foundation (ccf)international mrcc database consortium (imdc)memorial sloan kettering cancer center risk (mskcc)prognostic modelmetastatic renal cell carcinoma (rcc) |
| spellingShingle | Merve KESKİNKILIÇ Kübra CANASLAN Hüseyin Salih SEMİZ Tuğba YAVUZŞEN Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer Forbes Tıp Dergisi cleveland clinic foundation (ccf) international mrcc database consortium (imdc) memorial sloan kettering cancer center risk (mskcc) prognostic model metastatic renal cell carcinoma (rcc) |
| title | Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer |
| title_full | Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer |
| title_fullStr | Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer |
| title_full_unstemmed | Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer |
| title_short | Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer |
| title_sort | comparison of prognostic risk models imdc mskcc cff in patients diagnosed with metastatic renal cell cancer |
| topic | cleveland clinic foundation (ccf) international mrcc database consortium (imdc) memorial sloan kettering cancer center risk (mskcc) prognostic model metastatic renal cell carcinoma (rcc) |
| url | https://forbestip.org/articles/comparison-of-prognostic-risk-models-imdc-mskcc-cff-in-patients-diagnosed-with-metastatic-renal-cell-cancer/doi/forbes.galenos.2025.78309 |
| work_keys_str_mv | AT mervekeskinkilic comparisonofprognosticriskmodelsimdcmskcccffinpatientsdiagnosedwithmetastaticrenalcellcancer AT kubracanaslan comparisonofprognosticriskmodelsimdcmskcccffinpatientsdiagnosedwithmetastaticrenalcellcancer AT huseyinsalihsemiz comparisonofprognosticriskmodelsimdcmskcccffinpatientsdiagnosedwithmetastaticrenalcellcancer AT tugbayavuzsen comparisonofprognosticriskmodelsimdcmskcccffinpatientsdiagnosedwithmetastaticrenalcellcancer |